IP Library Granted Patent US 8,623,374
Granted Patent B2
US 8,623,374 · App. 13/220,452 · Granted Jan 7, 2014

Method for enhancing immune response with peptide

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,623,374
App. No.
13/220,452
Granted
Jan 7, 2014
Kind
B2
Abstract

An object of the present invention is to provide a safe and effective method for enhancing an immune response and a medicament for preventing or treating Alzheimer disease comprising amyloid β peptide that induces an enhanced immune response. An amyloid β peptide or a portion thereof with addition or insertion of cysteine and a method for enhancing an immune response using the peptide or a method for enhancing an immune response using the peptide together with an adjuvant. A medicament for preventing or treating Alzheimer disease comprising an amyloid β peptide or a portion thereof that induces an enhanced immune response. A DNA vaccine, that may have the same effect, comprising the gene encoding an amyloid β peptide or a portion thereof that induces an enhanced immune response with addition or insertion of cysteine.

Claims (8)

1. An immunogenic peptide that induces an enhanced immune response consisting of amino acids selected from the group consisting of the 1st-29th, 1st-30th, 1st-31st, 1st-35th, 1st-36th, 1st-37th, 1st-38th, 1st-39th, 1st-41st and 1st-42nd of an amyloid β peptide with the insertion of cysteine-between the 18th and 19th amino acid residues, between the 25th and 26th amino acid residues, or between the 28th and 29th amino acid residues counted from the N-terminus of the amyloid β peptide.

2. The immunogenic peptide according to claim 1 , wherein cysteine is inserted into the amyloid β peptide between the 18th and 19th amino acid residues counted from the N-terminus of the amyloid β peptide.

3. The immunogenic peptide according to claim 1 , wherein cysteine is inserted into the amyloid β peptide between the 25th and 26th amino acid residues counted from the N-terminus of the amyloid β peptide.

4. The immunogenic peptide according to claim 1 , wherein cysteine is inserted into the amyloid β peptide between the 28th and 29th amino acid residues counted from the N-terminus of the amyloid β peptide.

5. The immunogenic peptide according to claim 1 , wherein the amyloid β peptide consists of the amino acid sequence of SEQ ID NO: 34.

6. A medicament comprising the immunogenic peptide according to claim 1 as an active ingredient, and a pharmaceutically acceptable excipient.

7. A medicament comprising the immunogenic peptide according to claim 1 as an active ingredient, a pharmaceutically acceptable excipient, and an adjuvant.

8. A medicament comprising the immunogenic peptide according to claim 1 as an active ingredient, and a pharmaceutically acceptable excipient, with the proviso that the medicament does not comprise an adjuvant.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2020
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: KM BIOLOGICS CO., LTD.
Reel/Frame 051520/0971 →
CHANGE OF ADDRESS OF ASSIGNEE Recorded Apr 15, 2019
From: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 050169/0778 →
CHANGE OF NAME Recorded Jan 16, 2013
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029636/0944 →